The first evidence for a potential role of RGC-32 in MS came from experiments showing that RGC-32 is present in MS plaques in perivascular and parenchymal areas and co-localizes with CD3+ and CD68+ cells, indicating that inflammatory cells express RGC-32 in MS brains (27). This evidence concerns the gene CD68 and myeloid sarcoma.